转移性前列腺癌中抗前列腺特异性膜抗原抗体与其他免疫标志物的比较

Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.

作者信息

Chang S S, Reuter V E, Heston W D, Gaudin P B

机构信息

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.

出版信息

Urology. 2001 Jun;57(6):1179-83. doi: 10.1016/s0090-4295(01)00983-9.

DOI:10.1016/s0090-4295(01)00983-9

PMID:11377343

Abstract

OBJECTIVES

To compare the immunohistochemical properties of the 7E11 anti-prostate-specific membrane antigen (anti-PSMA) monoclonal antibody (mAb) with the recently developed anti-PSMA mAb, PM2J004.5, and with other common immunomarkers in metastatic prostate cancer. PSMA is a type II integral membrane glycoprotein highly expressed in prostate cancer cells. The mAb 7E11 is currently used in the radioisotopic evaluation of prostate cancer, and its immunohistochemical properties have been examined in primary prostate cancer specimens.

METHODS

We examined 23 formalin-fixed, paraffin-embedded, metastatic prostate carcinoma specimens from various anatomic sites, including bone, lymph node, liver, lung, and soft tissue. Using the biotin-streptavidin method, we performed immunohistochemical reactions with the anti-PSMA mAbs 7E11 and PM2J004.5 and with antibodies to prostate-specific antigen and prostatic acid phosphatase. The immunoreactions were scored by pathologists unaware of the clinical and pathologic data according to a staining intensity scale and the percentage of cells stained.

RESULTS

All four mAbs consistently stained the metastatic prostate cancer specimens. In 2 (8.7%) of 23 cases, however, the prostate-specific antigen immunoreaction was negative but the anti-PSMA mAbs had positive staining. Although 7E11 and PM2J004.5 had a similar staining intensity and percentage of cells stained for most specimens, in 3 (13%) of 23 specimens, 7E11 had less intense staining. None of the specimens were negative for all four antibodies.

CONCLUSIONS

Anti-PSMA mAbs consistently immunoreacted with metastatic prostate cancer specimens and were positive in instances when prostate-specific antigen staining was negative. The anti-PSMA mAbs demonstrated similar staining patterns; however, in select cases, the PM2J004.5 mAb did show more intense staining. The anti-PSMA mAbs 7E11 and PM2J004.5 are useful in the pathologic evaluation of paraffin-embedded metastatic prostate cancer specimens.

摘要

目的

比较7E11抗前列腺特异性膜抗原（抗PSMA）单克隆抗体（mAb）与最近研发的抗PSMA mAb PM2J004.5以及转移性前列腺癌中其他常见免疫标志物的免疫组化特性。PSMA是一种在前列腺癌细胞中高度表达的II型整合膜糖蛋白。mAb 7E11目前用于前列腺癌的放射性同位素评估，其免疫组化特性已在原发性前列腺癌标本中进行过检测。

方法

我们检查了23例来自不同解剖部位（包括骨、淋巴结、肝、肺和软组织）的福尔马林固定、石蜡包埋的转移性前列腺癌标本。使用生物素-链霉亲和素方法，我们用抗PSMA mAb 7E11和PM2J004.5以及前列腺特异性抗原和前列腺酸性磷酸酶抗体进行了免疫组化反应。病理学家在不知道临床和病理数据的情况下，根据染色强度量表和染色细胞百分比对免疫反应进行评分。

结果

所有四种mAb均一致地对转移性前列腺癌标本进行了染色。然而，在23例病例中的2例（8.7%）中，前列腺特异性抗原免疫反应为阴性，但抗PSMA mAb染色呈阳性。尽管对于大多数标本，7E11和PM2J004.5的染色强度和染色细胞百分比相似，但在23例标本中的3例（13%）中，7E11的染色强度较低。没有一个标本对所有四种抗体均呈阴性。

结论

抗PSMA mAb与转移性前列腺癌标本始终发生免疫反应，并且在前列腺特异性抗原染色为阴性的情况下呈阳性。抗PSMA mAb表现出相似的染色模式；然而，在某些情况下，PM2J004.5 mAb确实显示出更强的染色。抗PSMA mAb 7E11和PM2J004.5可用于石蜡包埋的转移性前列腺癌标本的病理评估。